Press Release Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes admin October 15, 2024
Press Release Seraxis wins grant from Maryland Stem Cell Research Fund to accelerate development of allogenetically compatible pancreatic islet replacement therapy for functional cure of T1D. admin June 14, 2024
Press Release Seraxis’ manufacturing suite completes GMP quality system audit ahead of SR-02 IND filing and transplantation of pancreatic clusters to patients with Type 1 Diabetes. admin January 4, 2024
Press Release Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA. admin October 26, 2023
Press Release Seraxis to provide oral update on its pancreatic organoid candidate for functional cure of T1D at the 59th Annual Meeting of the EASD. admin September 28, 2023
Press Release Seraxis announces closing of second VC tranche and successful completion of preclinical studies of pancreatic organoids from Seraxis’ novel pancreas-derived stem cells. admin September 20, 2023
Press Release Late-Breaking Results of a Preclinical Efficacy Study presented at ENDO 2023 show Seraxis SRE Sustainably Reverses Type-1-Diabetes Hyperglycemia. admin July 16, 2023
Press Release Seraxis Presents Successful Results Using Synthetic Replacement Endocrine Clusters for Type 1 Diabetes at the 4th IPITA / HSCI / JDRF Summit. admin April 25, 2023
Press Release Seraxis announces Appointment of Chief Medical Officer, Dr. Paul Strumph. admin August 30, 2022
